Stay updated with breaking news from S Relapse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Although serum glial fibrillary acid protein (GFAP) could be a useful complement to the multiple sclerosis biomarker neurofilament light chain (NfL), it is not ready for the clinic, experts say.
Two studies report few complications from continuing ocrelizumab and natalizumab into pregnancy, with high live birth rates, a decline in elective abortions, and few major congenital abnormalities in newborns.
Lower cardiorespiratory fitness predicts increased variability in stride time in people with MS and may serve as a biomarker of function decline.
Autologous hematopoietic stem cell transplantation is linked to significantly lower relapse rates than fingolimod in patients with relapsing-remitting multiple sclerosis. But adverse events are common.
Former employee/whistleblower to receive $250 million as part of settlement involving three drugs used to treat muscular sclerosis.